IL5RA and asthma: Since eosinophilic inflammation represents a specific endotype in asthma and other Th2-driven diseases [89], mAbs targeting IL-5 (mepolizumab and reslizumab) or IL-5R (benralizumab) have been successfully tested to treat severe refractory eosinophilic asthma, representing a therapeutic option [90].